Follow-up study for the KOI2-002 study in epidermolysis bullosa patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224722

Enrollment

Registered

2019-06-10

Start date

2019-07-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dystrophic epidermolysis bullosa

Interventions

investigational material(s) Generic name etc : S-005151 INN of investigational material : Redasemtide Therapeutic category code : 49- Other agents affecting cellular function Dosage and Administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with dystrophic epidermolysis bullosa who participated in the KOI2-002 study and received KOI2 treatment.

Exclusion criteria

Exclusion criteria: Patients who are considered inappropriate for the study by the investigator or subinvestigator

Design outcomes

Primary

Measure	Time frame
efficacy Percent change from baseline in the total area of blisters, erosions, and ulcers on the whole body by physician measurement	—

Secondary

Measure	Time frame
safety -Clinical laboratory tests (hematology test, blood chemistry test, urinalysis) -Adverse events (AEs), treatment-related AEs	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026